Whitehawk Therapeutics (NASDAQ:WHWK) Issues Earnings Results, Beats Estimates By $0.10 EPS

Whitehawk Therapeutics (NASDAQ:WHWK) released its quarterly earnings data on Thursday. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.10, Zacks reports.

Whitehawk Therapeutics Price Performance

WHWK opened at $4.70 on Friday. The company has a 50 day simple moving average of $4.11 and a two-hundred day simple moving average of $3.78. The firm has a market cap of $232.42 million, a P/E ratio of -2.80 and a beta of 0.76. Whitehawk Therapeutics has a 1-year low of $1.57 and a 1-year high of $5.49.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Citigroup started coverage on Whitehawk Therapeutics in a research note on Thursday, April 16th. They issued an “outperform” rating for the company. Leerink Partners began coverage on Whitehawk Therapeutics in a research report on Monday, July 13th. They set an “outperform” rating and a $9.00 price objective on the stock. B. Riley Financial began coverage on Whitehawk Therapeutics in a research report on Thursday, June 25th. They set a “buy” rating and a $10.00 price objective on the stock. Oppenheimer reiterated an “outperform” rating and issued a $7.00 price objective on shares of Whitehawk Therapeutics in a report on Friday, May 8th. Finally, Wall Street Zen cut shares of Whitehawk Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $8.20.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Orbimed Advisors LLC bought a new stake in Whitehawk Therapeutics during the third quarter valued at about $7,915,000. Acuta Capital Partners LLC purchased a new position in shares of Whitehawk Therapeutics in the third quarter valued at about $6,480,000. KVP Capital Advisors LP bought a new position in shares of Whitehawk Therapeutics in the fourth quarter worth about $5,242,000. Yu Fan bought a new position in shares of Whitehawk Therapeutics in the third quarter worth about $3,933,000. Finally, Vanguard Group Inc. purchased a new stake in shares of Whitehawk Therapeutics during the third quarter worth about $2,552,000. Hedge funds and other institutional investors own 52.08% of the company’s stock.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.